| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-04-04 | filgotinib | Sjögren's syndrome | 2 | Galapagos (Belgium) Gilead Sciences (USA - CA) | Autoimmune diseases - Ophtalmological diseases |
| 2017-04-04 | filgotinib | ankylosing spondylitis | 2 | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-04-04 | bavituximab | non-small-cell lung cancer (NSCLC) | 3 | Peregrine Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-04-04 | Rolontis™ (eflapegrastim) | chemotherapy-induced neutropenia | preclinical | Spectrum Pharmaceuticals (USA - NV) | Cancer - Oncology - Hematological diseases |
| 2017-04-04 | bispecific small molecules | preclinical | Evotec (Germany) Exscientia (UK) | Cancer - Oncology | |
| 2017-04-04 | VB-600 series | preclinical | VBL Therapeutics (Israel) | Cancer - Oncology | |
| 2017-04-03 | PI-2620 | Alzheimer's disease, Progressive Supranuclear Palsy (PSP) | preclinical, 1 | Piramal Imaging (India) AC Immune (Switzerland) | Neurodegenerative diseases |
| 2017-04-03 | A2A receptor antagonist | preclinical | iTeos Therapeutics (Belgium) | Cancer - Oncology | |
| 2017-04-03 | SD-101 | epidermolysis bullosa | 3 | Amicus Therapeutics (USA - NJ) | Rare diseases - Genetic diseases - Dermatological diseases |
| 2017-04-03 | ATIR201™ | beta-thalassemia major | 1-2 | Kiadis Pharma (The Netherlands) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-04-03 | 514G3 | Staphylococcus Aureus bacteremia | 1-2 | XBiotech (USA - TX) | Infectious diseases |
| 2017-04-03 | FPA008 (cabiralizumab) | preclinical | Five Prime Therapeutics (USA - CA) | Cancer - Oncology | |
| 2017-04-03 | Opdivo® (nivolumab) | previously treated advanced non-small cell lung cancer | 1b | BMS (USA - NY) | Cancer - Oncology |
| 2017-04-03 | Opdivo® (nivolumab) | first recurrence of glioblastoma multiforme (GBM) | 3 | BMS (USA - NY) | Cancer - Oncology |
| 2017-04-03 | Opdivo® (nivolumab)+Yervoy® (ipilimumab) | previously untreated advanced melanoma | 3 | BMS (USA - NY) | Cancer - Oncology |
| 2017-04-03 | VB-703 | NASH (non-alcoholic steatohepatitis), liver fibrosis | preclinical | VBL Therapeutics (Israel) | Liver diseases - Hepatic diseases |
| 2017-04-03 | VB-201 | NASH (non-alcoholic steatohepatitis), liver fibrosis | preclinical | VBL Therapeutics (Israel) | Liver diseases - Hepatic diseases |
| 2017-04-03 | ATIR101™ (Allodepleted T-cell ImmunotheRapeutics) | acute leukemia | 3 | Kiadis Pharma (The Netherlands) | Cancer - Oncology |
| 2017-04-02 | BeiGene-283/BGB-283 | B-RAF or K-RAS/N-RAS mutated solid tumors, pancreatic cancer | 1b | BeiGene (China) | Cancer - Oncology |
| 2017-04-01 | IPI-549 | advanced solid tumors | 1-1b | Infinity Pharmaceuticals (USA - MA) | Cancer - Oncology |
